Circovirus and impact of temporary withdrawal of rotavirus vaccines in Spain

Human Vaccines

Volumn 7, Issue 7, 2011, Pages 798-799

  Alejandro, Marta Bouzón ^a,b,c   Domingo, Javier Diez ^d   Torres, Federico Martinón ^a,b,c  

^a Instituto de Salud Carlos III   (Spain)

^b Santiago University Clinical Hospital   (Spain)

^c Galician Paediatric Research Network   (Spain)

^d Centro Superior de Investigacion en Salud Publica CSISP   (Spain)

Author keywords

Cost analysis; Infants; Public health; Rotavirus; Rotavirus vaccine

Indexed keywords

ROTAVIRUS VACCINE;

ACUTE GASTROENTERITIS; CIRCOVIRIDAE; CIRCOVIRUS; DRUG CONTAMINATION; DRUG COST; DRUG MARKETING; DRUG QUALITY; DRUG RECALL; DRUG SAFETY; GOOD MANUFACTURING PRACTICE; HEALTH CARE COST; HUMAN; NOTE; PHARMACY; PORCINE CIRCOVIRUS 1; PORCINE CIRCOVIRUS 2; PUBLIC HEALTH; RISK BENEFIT ANALYSIS; ROTAVIRUS INFECTION; SPAIN; VACCINATION; VACCINE PRODUCTION;

CHILD; CIRCOVIRUS; DNA, VIRAL; HUMANS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SAFETY-BASED DRUG WITHDRAWALS; SPAIN; VACCINES, ATTENUATED;

EID: 79960751524     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.7.15683     Document Type: Note

References (9)

1. Spanish Pediatric Association. [Detection of circovirus DNA in vaccines against rotavirus: Consensus document of scientific societies AEP AEV, SEIP, SEGHNP. June 2010]. Available at: http://www.vacunasaep.org/rotavirus-consenso- 2010-2.htm (last access feb 2011).
2. Martinón-Torres F, Alejandro MB, Collazo LR, Lastres JM, Díaz SP, Pillado MT, Sánchez JM. Effectiveness of rotavirus vaccination in Spain. Hum Vaccin 2011; 7:In press.
3. Giménez-Sánchez J, Salvador-Sánchez E, Cobos-Carrascosa M, Sánchez Forte W, Sánchez-Yebra E, López-Ruzafa1 A, Bonillo-Perales. Decline in rotavirus hospitalized cases in spain after the introduction of oral rotavirus vaccines. Presented at 27th Annual Meeting of the European Society of Pediatric Infectious Disease (ESPID), Brussels (Belgium), 9-13 june 2009. Available at: http://www.kenes.com/espid09/ abstracts/pdf/987.pdf (last access feb 2011).
4. National Institute of Statistics - Instituto nacional de Estadística (INE). Demografía y población. Available at: http://www.ine.es/inebase (last access feb 2011).
5. Diez-Domingo J, Baldo JM, Patrzalek M, Pazdiora P, Forster J, Cantarutti L, et al. Primary care-based surveillance to estimate the burden of rotavirus gastroenteritis among children aged less than 5 years in six European countries. Eur J Pediatr 2011; 170:213-22.
6. Diez-Domingo J, Oyaguez I, Ballester A, Gonzalez A, Casani C, Peidro C, et al. Rotavirus gastroenteritis among children under five years of age in Valencia, Spain. Pediatr Infect Dis J 2006; 25:455-7.
7. Diez-Domingo J, Lara Suriñach N, Malé Alcalde N, Betegón L, Largeron N, Trichard M. Burden of paediatric rotavirus gastroenteritis (RVGE) and potential benefits of a universal rotavirus vaccination programme with a pentavalent vaccine in Spain. BMC Public Health 2010; 10:469.
8. Giaquinto C, Van Damme P, Huet F, Gothefors L, Van der Wielen. REVEAL Study Group. Cost of community-acquired pediatric rotavirus gastroenteritis in 7 european countries: The REVEAL study. J Infect Dis 2007; 195:36-44.
9. Martinon-Torres F, Bouzon-Alejandro M, Redondo-Collazo L, Sanchez-Lastres J, Martinon-Sanchez JM, ROTACOST Investigators Group from ReGALIP. Indirect costs caused by acute rotavirus gastroenteritis in Spain. Pediatric Research 2010; 250.